The prostate cancer news has been very “light” for the past few days. Even today’s new reports offer very little new information.
Filed under: Drugs in development, Management, Prevention, Risk, Treatment | Leave a Comment »
Another new “vaccine” enters clinical trials
Posted on August 6, 2009 by Sitemaster
According a media release earlier today, Bellicum Pharmaceuticals, Inc. has announced dosing of their first patient in a Phase I/II clinical trial of “BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer.”
Filed under: Drugs in development, Management, Treatment | Tagged: BP-GMAX-CD1, castration-resistant prostate cancer, CRPC, vaccine | 3 Comments »
OncoGenex and development plans for OGX-011
Posted on August 5, 2009 by Sitemaster
For readers who are interested in OncoGenex Pharmaceuticals‘ plans for the future development of Phase III trial of OGX-011 (an antisense compound that acts as a clusterin growth inhibitor), it’s worth reading Luke Timmerman’s article on Xconomy.com, which is based on a recent interview with OncoGenex’s CEO, Scott Cormack.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, OGX-011 | Leave a Comment »
The surgical treatment of locally advanced disease: an update
Posted on August 5, 2009 by Sitemaster
BJU International has just published a new review of the issues affecting the role of surgery as a form of treatment for men with locally advanced prostate cancer.
Filed under: Diagnosis, Management, Treatment | Leave a Comment »
Prostate cancer news reports: Wednesday, August 5, 2009
Posted on August 5, 2009 by Sitemaster
Apparently Ferring Pharmaceuticals has finally been able to get Firmagon® approved as the new trade (brand) name for degarelix (their new LHRH antagonist) here in the USA. This is the same brand name as is used in Europe. Who knows why it took so long! The media release doesn’t say. In other news reports today [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: Degarelix, Height, quality of care, survival, tallness, vitamin B-6 | Leave a Comment »
More on the topic of prostate cancer risk
Posted on August 4, 2009 by Sitemaster
Two studies published recently add some additional information to our understanding of prostate cancer risk assessment in specific groups of patients.
Filed under: Diagnosis, Risk | Leave a Comment »
The impact of exercise on side effects of ADT
Posted on August 4, 2009 by Sitemaster
It has long been known that androgen deprivation therapy (ADT), when used in the long-term treatment of men with prostate cancer, is accompanied by not only hot flashes and effects on cognition but also by bone loss, increased risk for fracture, loss of muscular strength, mood disturbances, and fat-based weight gain, all of which affect [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, exercise, Phase III trial | Leave a Comment »
What cost prostate cancer treatment?
Posted on August 3, 2009 by Sitemaster
Many readers will be interested in the article titled “Debate surrounds new prostate-cancer treatment” that appeared today in the Philadelphia Inquirer on the topic of prostate cancer treatment costs.
Filed under: Management, Treatment | Tagged: coverage, CyberKnife, radiotherapy | 5 Comments »
The problem with clinical trials …
Posted on August 3, 2009 by Sitemaster
… is that (at least on a national basis) way too few cancer patients participate (for a variety of reasons).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: clinical trials, enrollment | 6 Comments »
Prostate cancer news reports: Sunday, August 2, 2009
Posted on August 2, 2009 by Sitemaster
Only two news reports of any significance this weekend, on: Pesticides and prostate cancer risk in Martinique The transition from hormone-sensitive to hormone-refractory disease
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: castration-resistant, hormone refractory, hormone-sensitive, incidence, Martinique, pesticides, risk | Leave a Comment »
“I am a dosimeter” (the tissue effects of PBRT)
Posted on August 2, 2009 by Sitemaster
The text and the image below have been kindly submitted by HAK (a patient and a respected clinician) as a reference source regarding the distinctions between the effects of proton beam radiation therapy (PBRT) and other types of external beam radiotherapy, particularly intensity-modulated radiation therapy (IMRT) in the treatment of localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: effects, PBRT, proton beam radiation therapy | 16 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
